Evidence map›Paper›PMID 37885370›Full record

ArticleInfluenza and other respiratory viruses2023

A model for public-private partnership during the COVID-19 pandemic: Lessons from Biolab and public laboratories working in the Hashemite Kingdom of Jordan.

Issa Abu-Dayyeh, Zein Naber, Luke W Meredith, Lora Alsawalha, Dana Nassar, Lara Sumrain, Mohammad Ghunaim, Thaer Hasan, Amid Abdelnour

Open access · goldAbstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Issa Abu-DayyehDepartment of Research and Development, Biolab Diagnostic Laboratories, Amman, Jordan.ORCID 0000-0003-0224-2292
Zein NaberDepartment of Research and Development, Biolab Diagnostic Laboratories, Amman, Jordan.
Luke W MeredithInfectious Hazard Management, Department of Health Emergency, World Health Organization, Eastern Mediterranean Regional Office, Cairo, Egypt.
Lora AlsawalhaJordan Country Office, World Health Organization, Amman, Jordan.
Dana NassarDepartment of Research and Development, Biolab Diagnostic Laboratories, Amman, Jordan.
Lara SumrainDepartment of Research and Development, Biolab Diagnostic Laboratories, Amman, Jordan.
Mohammad GhunaimDepartment of Research and Development, Biolab Diagnostic Laboratories, Amman, Jordan.
Thaer HasanDepartment of Research and Development, Biolab Diagnostic Laboratories, Amman, Jordan.
Amid AbdelnourDepartment of Research and Development, Biolab Diagnostic Laboratories, Amman, Jordan.
Medical Diagnostic Laboratories (United States) · USWorld Health Organization - Pakistan · PKWorld Health Organization Regional Office for the Eastern Mediterranean · EG

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionThe global COVID-19 pandemic overwhelmed national public health and laboratory capacity in Jordan and globally. In response, Biolab, a private laboratory group with 27 branches across Jordan, assisted with testing. Biolab was equipped to quickly increase molecular testing capacity without compromising quality or turnaround time, allowing them to contribute to national COVID-19 surveillance efforts.

methodsBiolab expanded testing in Jordan by operationalizing automated testing platforms at various locations, including 16 branches, 2 drive-through and 2 walk-through centres, and entry points for airports and marine passenger arrivals. Genomic and molecular testing were implemented to track variants. Information technology platforms were introduced for sample management, registration, and commercial sample payments. Data were directly provided to the Ministry of Health through these platforms to support public health decision-making and responses. Biolab prioritized staff well-being by providing mental, financial, and physical health support during the pandemic.

resultsBiolab processed more than two million samples, with a turnaround time of ~1.5 h. Results were transmitted directly to key stakeholders in near real time. Biolab conducted variant evaluations on >1.4 million samples using molecular variant testing and >1000 samples using whole genome sequencing. Biolab prioritized staff well-being, improving staff satisfaction from 74% to 91%, a remarkable achievement when many laboratory systems experienced staff burnout and dissatisfaction.

conclusionThe collaboration between public and private laboratories during COVID-19 established a model for future joint efforts to prevent outbreaks from becoming pandemics. Biolab's focus on efficiency, quality, and staff well-being enabled consistent, high-quality performance. The introduction of innovative information technology platforms ensured swift information dissemination. Biolab plans to continue investing in these platforms and expand pathogen testing, creating a top-tier testing infrastructure in Jordan with a demonstrated ability to cooperate with the government for public benefit.

Indexed as

COVID-19HumansJordanLaboratoriesPandemicsPublic-Private Sector PartnershipsBiolabCOVID-19JordanNGSPCRpublic-private partnerships

Identifiers

PMID37885370
PMCPMC10627090
OpenAlexW4387746867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.